Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$1.58
+3.9%
$1.43
$1.05
$5.17
$164.59M0.381.19 million shs507,657 shs
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
$0.22
$2.64
$3.50
$1.21B0.5729,710 shsN/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
$1.34
+0.8%
$1.04
$0.81
$1.82
$69.10M1.49198,733 shs279,702 shs
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$33.52
+0.0%
$32.36
$27.05
$40.28
$1.88B0.7490,215 shs1.20 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
+3.95%+2.60%+9.72%+38.60%+17.91%
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
0.00%0.00%0.00%0.00%-0.19%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
+0.75%+3.88%+25.23%+31.37%-20.24%
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
+0.03%+2.60%+3.23%+8.97%+15.83%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
2.0195 of 5 stars
3.61.00.00.02.01.70.6
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
3.1551 of 5 stars
3.53.00.00.03.32.50.6
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
1.6492 of 5 stars
1.21.00.04.13.30.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
3.11
Buy$8.71451.54% Upside
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
0.00
N/AN/AN/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
3.00
Buy$5.50310.45% Upside
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
2.33
Hold$36.007.40% Upside

Current Analyst Ratings Breakdown

Latest ACRS, ATBPD, SUPN, and PMVP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$6.00
6/25/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/23/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$8.00
5/28/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$8.00
5/14/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $16.00
5/9/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $9.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$18.72M9.14N/AN/A$1.44 per share1.10
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
$7.51M0.00N/AN/A$0.10 per share0.00
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/AN/AN/AN/A$3.40 per shareN/A
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$661.82M2.84$4.17 per share8.03$18.76 per share1.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$132.07M-$1.39N/AN/AN/A-732.42%-30.73%-22.74%8/6/2025 (Estimated)
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
-$14.54M-$0.60N/AN/AN/A-273.96%-150.49%-98.51%N/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-$58.71M-$1.18N/AN/AN/AN/A-32.54%-29.59%8/6/2025 (Estimated)
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$73.86M$1.1130.2023.28N/A9.27%12.23%9.17%8/5/2025 (Estimated)

Latest ACRS, ATBPD, SUPN, and PMVP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-$0.39N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$0.14N/AN/AN/A$1.34 millionN/A
8/5/2025Q2 2025
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$0.47N/AN/AN/A$154.06 millionN/A
5/9/2025Q1 2025
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-$0.37-$0.34+$0.03-$0.34N/AN/A
5/6/2025Q1 2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$0.19-$0.12+$0.07-$0.12$3.55 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/AN/AN/AN/AN/A
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
N/AN/AN/AN/AN/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/AN/AN/AN/AN/A
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/A
5.06
5.06
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
N/A
5.97
5.42
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/A
16.75
16.75
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/A
2.44
2.26
CompanyEmployeesShares OutstandingFree FloatOptionable
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
100108.28 million101.35 millionOptionable
Antibe Therapeutics Inc. stock logo
ATBPD
Antibe Therapeutics
47387.00 millionN/ANot Optionable
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
5051.95 million48.02 millionOptionable
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
58055.99 million51.06 millionOptionable

Recent News About These Companies

Supernus Pharmaceuticals, Inc. (SUPN) - Yahoo Finance
Sage Sacks Entire Staff After Supernus Buyout

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aclaris Therapeutics stock logo

Aclaris Therapeutics NASDAQ:ACRS

$1.58 +0.06 (+3.95%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$1.60 +0.02 (+1.58%)
As of 09:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Antibe Therapeutics stock logo

Antibe Therapeutics OTCMKTS:ATBPD

Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

PMV Pharmaceuticals stock logo

PMV Pharmaceuticals NASDAQ:PMVP

$1.34 +0.01 (+0.75%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$1.35 +0.01 (+0.67%)
As of 04:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Supernus Pharmaceuticals stock logo

Supernus Pharmaceuticals NASDAQ:SUPN

$33.52 +0.01 (+0.03%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$33.30 -0.22 (-0.66%)
As of 09:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.